PGR and neoplasm: Depending on the gene and protein expression differences between luminal A and B tumours and their clinicopathologic features and survival outcomes, Prat et al. [2] proposed an empiric cut-off point of 20% for PgR to better distinguish luminal A from luminal B breast cancer.